Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAcerand Therapeutics (Shanghai) Limited
About this trial
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
Eligibility criteria
Qualifiers
Provide written informed consent;
Advanced solid tumors, difficult to treat or intolerant to standard treatment, suitable for investigational treatment;
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
Has a life expectancy of at least 3 months;
Disqualifiers
Receiving any anti-cancer drugs, major surgery, extensive radiation therapy, or local radiation therapy within protocol-defined wash-out period;
Concomitant use of medications or herbal supplements known to be strong or moderate inhibitors or inducers of cytochrome P450 3A4 (CYP3A4);
Receiving continuous corticosteroid treatment with a dose of prednisone greater than 10 mg/day or an equivalent dose.
Receiving continuous treatment with prednisone at a dose of >10 mg/d or other corticosteroids at an equivalent dose for any reason.
Trial design
Treatments tested in this trial
- ACE-86225106 tablet
Treatment groups
298 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov